Shorts

2:06
PNS 2026: Debate Between iPSC and Animal Models for Neuropathy Research
3 months ago
by
Ahmet Hoke, MD, PhD

1:13
AHS 2026: Real-World INFUSE Trial of Eptinezumab in Migraine
3 months ago
by
Amaal J. Starling, MD(+1 more)

1:06
SLEEP 2026: Phase 2 Study of Alixorexton in Narcolepsy Type 2
3 months ago
by
Richard Bogan, MD, FCCP, FAASM(+1 more)

0:50
Adapting Exercise for Neurologic Conditions
3 months ago
by
Mitzi Joi Williams, MD

0:58
RECAP: Neurology News Network - June 20th
3 months ago
by
Louie Pasculli

0:35
Steps Needed to Make Diabetic Peripheral Neuropathy Reversible
3 months ago
by
Brian Callaghan, MD, MS

0:57
SLEEP 2026: Key Takeaways From New Hospital-Based Sleep Apnea Guidelines
3 months ago
by
Sunil Sharma, MD(+1 more)

1:04
SLEEP 2026: What Is a Common Sleep-Related Question?
3 months ago
by
Beth Malow, MD, MS(+1 more)

1:11
ATMRD 2026: Overlooked Symptoms of Autonomic Dysfunction in PD
3 months ago
by
Louie Pasculli(+2 more)

1:09
SLEEP 2026: AASM Guideline for Treating Chronic Insomnia
3 months ago
by
Salma Patel, MD(+1 more)

0:35
Biggest Misconceptions Regarding Immune-Mediated Small Fiber Neuropathy
4 months ago
by
Matthew Evans, BM, BCh, DPhil

0:25
Goals for Expanding Knowledge on Programmed Axon Death
4 months ago
by
Michael Coleman, PhD

0:20
Improving Basic Science Objectives for Peripheral Nerve Disorders
4 months ago
by
Carla Taveggia, PhD

0:20
Confocal Corneal Microscopy as an Emerging Biomarker for Peripheral Nerve Disorders
4 months ago
by
Brett Morrison, MD, PhD

0:32
Addressing an Overlooked Gap in MS Clinical Trials
4 months ago
by
Louie Pasculli(+1 more)

0:20
Key Areas of Neuropathy Research: Keeping and Optimizing Animal Models
4 months ago
by
Ahmet Hoke, MD, PhD

0:48
Underexplored, Emerging Biomarkers for ALS
4 months ago
by
Jinsy A. Andrews, MD, MSc

0:56
Exploring the Possibility of Treating ALS in the Prodromal Stage
4 months ago
by
Jinsy A. Andrews, MD, MSc

1:04
ATMRD 2026: Redefining Wellness in Parkinson Disease
4 months ago
by
Louie Pasculli(+1 more)

0:56
Emerging Retinal Biomarkers of Neurodegeneration
4 months ago
by
Dimitra Skondra, MD, PhD

1:21
CMSC 2026: Key Highlights in Multiple Sclerosis Care
4 months ago
by
Carrie Hersh, DO, MSc, FAAN(+1 more)

0:47
ATMRD 2026: The Future of Clinical Trials Is Closer to Home
4 months ago
by
David Shprecher, DO, MSci, FAAN(+1 more)

1:07
CMSC 2026: Aging and Treatment Strategies in MS
4 months ago
by
Amy Gutierrez, MD, FAAN(+1 more)

1:52
RECAP: Neurology News Network - June 6th
4 months ago
by
Louie Pasculli

1:34
ATMRD 2026 Session Spotlight: Experiencing Parkinson Speech Therapy Firsthand
4 months ago
by
Anissa Mitchell, LCSW(+1 more)

0:35
Call to Action: Why Clinicians Should Explore ISSCR's New Stem Cell Course
4 months ago
by
Claire Henchcliffe, MD, DPhil

2:27
How Stem Cells Differ From Levodopa
4 months ago
by
Claire Henchcliffe, MD, DPhil

1:25
The Science Behind Cell Replacement
4 months ago
by
Roger A. Barker, MD, PhD

1:25
CMSC 2026: Cognitive Screening in Multiple Sclerosis
4 months ago
by
Elizabeth S. Gromisch, PhD(+1 more)

1:27
How to Counsel Patients on Emerging Stem Cell Treatments
4 months ago
by
Claire Henchcliffe, MD, DPhil
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP
4
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
5
